Related Experiment Video
Updated: Jul 14, 2026
09:03
Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
Published on: June 30, 2023
Type IV collagen-derived angiogenesis inhibitors.
Thomas M Mundel1, Raghu Kalluri
1Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Microvascular Research
|July 3, 2007
Summary
Anti-angiogenesis therapy, introduced in 1971, targets new blood vessel formation. This review focuses on type IV collagen-derived inhibitors like Arresten, Canstatin, and Tumstatin, crucial for regulating pathological angiogenesis.
Area of Science:
- Biomedical Science
- Molecular Biology
- Pathology
Background:
- Angiogenesis, the formation of new blood vessels, is tightly regulated by pro- and anti-angiogenic factors.
- In healthy adults, the "angiogenic-switch" is typically "Off," with anti-angiogenic factors dominating.
- Dysregulated angiogenesis is implicated in various diseases, including cancer, arthritis, and retinopathy.
Purpose of the Study:
- To review the role of endogenous angiogenesis inhibitors.
- To specifically focus on type IV collagen-derived inhibitors: Arresten, Canstatin, and Tumstatin.
- To highlight their significance in controlling pathological angiogenesis.
Main Methods:
- Literature review of scientific studies on angiogenesis.
- Analysis of endogenous angiogenesis inhibitors derived from extracellular matrix (ECM) proteins.
- Focus on specific type IV collagen fragments and their inhibitory mechanisms.
Main Results:
- Identification of numerous pro- and anti-angiogenic factors since 1971.
- Confirmation that angiogenesis is crucial in both physiological and pathological processes.
- Emergence of ECM-derived peptides as potent endogenous angiogenesis inhibitors.
Conclusions:
- Type IV collagen fragments like Arresten, Canstatin, and Tumstatin are significant endogenous inhibitors of angiogenesis.
- These inhibitors offer potential therapeutic strategies for diseases characterized by aberrant angiogenesis.
- Further research into these inhibitors could lead to novel anti-angiogenesis therapies.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:05Type IV Collagen of Basal Lamina
Type IV collagen is a 400 nm long, network-forming collagen that acts as a barrier between the epithelial and endothelial cells. Type IV collagen forms the backbone of the basement membrane by scaffolding with laminin, entactin, proteoglycans, and fibronectin. Apart from rendering structural support to the basement membrane, it also helps entail signaling potentials necessary for both pathological and physiological functions.
A type IV collagen molecule has six alpha chains which can exist in...
A type IV collagen molecule has six alpha chains which can exist in...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...